Building or investing in the RNA therapeutics market? Get our report

RNA medicines are big business today, but it's a nervous market: one regulatory twist or one weak quarter can move the whole field.

We've found a lot of interesting signals. For example, in February 2026, the FDA refused to review Moderna's mRNA flu vaccine, changed course a week later, and approved it in August for adults 50 and older. In July, Alnylam's Amvuttra, a drug for a rare heart and nerve disease, passed $1B in sales in a single quarter, yet the stock fell as much as 29% when the company cut its outlook. RNA drugs now reach patients at scale, but regulators and investors leave very little room for surprises.

In this section, we look at why RNA drugs keep winning approvals despite the pressure on mRNA in the US, which types of RNA medicines sell best, and what these swings mean for younger companies that still need to raise money.

Many diseases come from a protein that pills and antibodies can't reach. RNA drugs can switch that protein off, or tell cells to make a missing one, but getting them to the right tissue is still hard.

We look at six types of companies, from siRNA and antisense developers to mRNA makers, RNA editing startups and delivery platforms. Their buyers and partners are mostly big pharma, along with specialists in heart, rare and brain diseases. For each, we rank the biggest pains, like reaching tissues beyond the liver, the cost of large trials in common diseases, and immune reactions to the drug or its carrier.

This shows which problems partners will pay to solve today, and which ones still need better delivery first.

RNA companies make money in several ways: selling their own drugs, licensing programs to big pharma for upfront payments and milestones, earning royalties, and renting out their delivery or manufacturing platforms.

We compare who pays and what each path costs. A rare disease drug can sell at a high price to a small group of patients, with a small sales team. A heart drug for millions needs huge outcome trials and has to compete with cheap pills. A platform deal brings cash early, but often hands the biggest programs and most of the upside to the partner.

You'll see which models bring in steady cash, and which ones only pay off if a drug wins a large outcome trial.

Our growth estimate depends on a handful of forces. We take them one at a time here.

Some drivers are clear: drugs that need only a few injections a year, a long list of targets other drugs can't reach, and steady pharma money. Others feed each other. Each approval in a common disease makes doctors and insurers more open to the next one. Better delivery opens new organs. And newer tools like RNA editing and self-amplifying RNA give the field more ways to treat the same disease.

Before building or investing, you should know what it takes for an RNA drug to move from a rare disease to millions of patients, and keep its price.

Alnylam is the name most people know in RNA drugs, but the field is far bigger than one company.

Many smaller companies work on one piece of the puzzle. Some design carriers that reach muscle, brain or fat tissue. Others edit single letters of RNA to fix a genetic error, or make circular RNA that lasts longer inside cells. A growing number in China license their siRNA programs to big pharma before reaching late trials.

They're hard to compare because an siRNA drug, an mRNA medicine and an RNA editor have little in common beyond the molecule. Many also work inside pharma deals, so their best data and most of their revenue stay out of public view.

Below, you'll find the market grids and ecosystem maps we've built to show who works on which type of RNA, for which disease, and where new players are getting in.

Ionis, Arrowhead Pharmaceuticals, Arcturus Therapeutics… a few RNA companies have turned their science into approved products. They took very different routes, and not all have shown they can make money.

Ionis lived for years on royalties from partners, and now launches its own antisense drugs: Tryngolza won a wider approval in June 2026. Arrowhead funded itself with pharma deals until its first own siRNA drug, Redemplo, was approved in November 2025. Arcturus and its partner CSL won European approval for the first self-amplifying mRNA COVID vaccine. One bet on selling alone, one on partners first, one on a new kind of RNA.

We'll look at how these teams picked their first disease, decided when to sell alone or through a partner, and paid for trials before the first sales came in.